Feeds:
Posts
Comments

Archive for the ‘Statins’ Category

*****

TODAY’S NEWS:

Abbott making a big India buy – The speculation that has been fuelling the shares of Piramal Healthcare over the past few days has been put to rest after Abbott Laboratories announced Friday that it will buy a unit of the Indian pharmaceutical companymore

Lots of Oncology. Rituxan: cutting lymphoma recurrence – The final phase of a drug study finds that two years of treatment with rituximab (Rituxan) cuts in half the risk that follicular lymphoma patients who respond to chemotherapy will suffer a recurrence of the diseasemore And, some good news on sarcoma: An experimental drug from Ziopharm Oncology Inc. helped keep fast-growing sarcomas, lethal tumors that can grow to the size of basketballs, in check 77% longer than a standard treatment, a company-sponsored study foundmore Plus, Amgen experimental drugs slow down some tumors.

Some side effects of popular cholesterol-lowering drugs? – Drugs to lower cholesterol and prevent heart disease, taken by millions of people worldwide, increase the risk of cataracts, kidney failure, muscle pain and liver dysfunction, a study of more than 2 million Britons foundmore

RECOMMENDED

Social Media Community/Facebook Moderation and Management. Our social media partners offer a range of services, including community moderation and platform design. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The Doctor Won’t See You Now training.

JUST FOR FUN

It’s spring, and the weather’s fine. So, go on one of America’s Scenic Drives.

AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Advertisements

Read Full Post »

*****

TODAY’S NEWS

AstraZeneca still waiting for the upside of MedImmune acquisition.

Pfizer: More Lipitor, fewer heart complications – A reanalysis of research data found a high dose of popular cholesterol pill Lipitor lowers risk of heart attack and stroke in some patients with both heart disease and kidney disease, the drug’s maker said Mondaymore

Fred Hassan heads to Bausch & Lomb.

Novartis‘ Tekturna post-heart attack: Not a good idea. “Given these results, we are not currently recommending the use of this agent in addition to other inhibitors of the renin-angiotensin system in this specific patient population.”

Access to docs flat, but appointments on the rise.

RECOMMENDED

eLearning Development – From modules to virtual preceptorships to virtual worlds, we’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

“I hate her uterus!” DTC, infertility, and a very effective on-line campaign. IncreaseYourChances.

JUST FOR FUN

Human, squirrel, or anvil? A great Dilbert cartoon today!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

Pfizer‘s oncology drug Sutent slows down pancreatic cancer spread – Pfizer Inc.  said Sutent, its drug for kidney cancer, also helps stop the progression of a kind of pancreatic cancer, according to a late-stage trial. Sutent is in several late-stage studies to investigate expanding its use beyond kidney and gastrointestinal treatment, exploring its efficacy in treating breast and lung cancer, among others. In the most recent study of patients with advanced tumors originating in the hormone-production area of the pancreas, disease progression was halted for more than twice as long with Sutent versus a placebo..more

Quintiles re-brands: Navigating the New Health.

In pharma-world, people often joke about how we should just put statins in the drinking water. Here’s some insight as to why (don’t shoot the messenger – I know there are plenty of detractors!)

Doc gives up hospital post over conflict-of-interest rules.

RECOMMENDED

Business Acumen – We have partners who will help your leaders and individual contributors acquire and analyze industry, market, operational and financial information, and apply insights from that analysis to develop strategies and make better business decisions. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Prilosec making a big venture into social media: a good move? – Procter & Gamble has launched a new online social media site for Prilosec OTC focused on winning new customers by talking up the lifestyle difficulties of heartburn sufferers. In an increasingly crowded market for over-the-counter heartburn medicines, is it worth spending millions more on an advertising campaign for a mature product with declining sales volumes?more

JUST FOR FUN

Advertising on a bus – how to be way too creepy!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Crestor – now no high cholesterol needed!

Ah, lawyers. NJ, the judicial hellhole. And, the video Pfizer doesn’t want you to see.

Rare diseases and big pharma.

RECOMMENDED

Compliance training. The Impactiviti network has great suppliers for all your corporate compliance needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

VaxTrak – Novartis launches a first-version of an iPhone app for tracking your childrens’ vaccinations. I like it.

JUST FOR FUN

15 Stupidest Warning Labels. Some real winners here!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

So, have we been pursuing the wrong course for GERD all this time? Is it actually caused by immune system cells, not stomach acid?

Maybe cheap/old/tried-and-true really is better. Diuretics for HPB, for instance. Or just plain generic simvastatin for cholesterol.

Pfizer gets good news on Revatio (which is the same as Viagra, by the way) for the treatment of PAH; Spiriva for COPD; and the Prevnar 13 vaccine.

Genzyme: Train wreck?. But wait – there’s more.

Getting excited about sex: not so easy to be excited about B-I‘s experimental treatment for female desire; Vivus‘ competitor to current ED drugs still on track, however.

RECOMMENDED

Marketing/Sales – tele-detailing. Is your company looking to augment its promotional voice with telesales, virtual detailing, and other “surround sound” solutions? Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Blind Spots and Broken Limbs. I’ve got them, too…

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

FTC says “yes” to Merck-Schering merger.

AstraZeneca’s experimental drug Brilinta may not get along well with aspirin: AstraZeneca Plc is looking into whether greater use of aspirin reduces the effectiveness of its experimental clot-busting medicine Brilinta, which analysts had estimated would bring in $1 billion a yearmore Plus, AZ agrees to a $520M fine in Seroquel marketing probe. Ouch.

Medical Marketing and Media agency awards for this year. It was an in-house effort that picked up the Gold Award for Best Integration Program for Large Companies.

Statins and flu: med may be good for more than high cholesterol? – Doctors may have a new treatment for swine flu that’s already on pharmacy shelves — cholesterol-lowering statin drugs like Pfizer’s Lipitor and Zocor. Researchers reported Thursday that people who were already on these drugs when they caught seasonal flu and had to be hospitalized were twice as likely to survive than those not on such medicinesmore

RECOMMENDED

Train-the-Trainer. Impactiviti’s partner network includes a wonderful provider who can customize a train-the-trainer program for your department. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

When Statistics have Faces. A reminder of the humanity in everything we do. Also, an amazing animation of how the flu virus infects your body.

JUST FOR FUN

Landscape Photo of the Year. And other lovely contenders.
Coming up next week:

eComm

Nov. 3-4 – eyeforpharma’s 4th Annual eCommunication and On-line Marketing Summit, Philadelphia, PA. I’ll be part of a panel on social networking, and live-blogging/Twittering. Here’s a discount code to save $400 off your registration: SPEAK

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Combo pills for high cholesterol: no better than higher doses of single drug? Interesting study results.

Should we really be doing all those PSA tests for prostate cancer? Maybe not.

Shire‘s Gaucher drug on the fast track, due to Genzyme manufacturing problems.

A NY Times interview with Deborah Dunsire, CEO of Millennium – good focus on leadership development.

RECOMMENDED

Managed Care Training. The Impactiviti Partner network is rich with great managed care training providers, from off-the-shelf content to live workshops to consulting expertise to training events.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

FDA silence about social media guidance “a problem,” according to a Pfizer exec. Agreed.

JUST FOR FUN

Here’s a lightning bolt you definitely would not want to see up-close and personal. Wow!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Older Posts »